Insider Transactions in Q3 2024 at Alumis Inc. (ALMS)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 01
2024
|
James B. Tananbaum Director |
BUY
Open market or private purchase
|
Indirect |
2,500,000
+19.77%
|
$40,000,000
$16.0 P/Share
|
|
Jul 01
2024
|
James B. Tananbaum Director |
BUY
Conversion of derivative security
|
Indirect |
11,476,484
+32.61%
|
-
|
|
Jul 01
2024
|
Foresite Capital Management V, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,500,000
+19.77%
|
$40,000,000
$16.0 P/Share
|
|
Jul 01
2024
|
Foresite Capital Management V, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
11,476,484
+32.61%
|
-
|
|
Jul 01
2024
|
Foresite Labs, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,500,000
+19.77%
|
$40,000,000
$16.0 P/Share
|
|
Jul 01
2024
|
Foresite Labs, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
11,476,484
+32.61%
|
-
|
|
Jul 01
2024
|
Ayur Maya Capital Management Company, LP Director |
BUY
Grant, award, or other acquisition
|
Indirect |
2,500,000
+19.02%
|
$40,000,000
$16.0 P/Share
|
|
Jul 01
2024
|
Ayur Maya Capital Management Company, LP Director |
BUY
Conversion of derivative security
|
Indirect |
8,145,966
+50.0%
|
-
|
|
Jul 01
2024
|
Sara Klein General Counsel - Corp Secy |
BUY
Grant, award, or other acquisition
|
Direct |
33,796
+50.0%
|
-
|
|
Jul 01
2024
|
Sara Klein General Counsel - Corp Secy |
SELL
Sale (or disposition) back to the issuer
|
Direct |
33,796
-100.0%
|
-
|
|
Jul 01
2024
|
Srinivas Akkaraju |
BUY
Grant, award, or other acquisition
|
Indirect |
1,703,998
+50.0%
|
-
|
|
Jul 01
2024
|
Srinivas Akkaraju |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,703,998
-100.0%
|
-
|
|
Jul 01
2024
|
Srinivas Akkaraju |
BUY
Conversion of derivative security
|
Indirect |
1,703,998
+50.0%
|
-
|
|
Jul 01
2024
|
Zhengbin Yao |
BUY
Grant, award, or other acquisition
|
Direct |
23,529
+50.0%
|
-
|
|
Jul 01
2024
|
Zhengbin Yao |
SELL
Sale (or disposition) back to the issuer
|
Direct |
23,529
-100.0%
|
-
|
|
Jul 01
2024
|
Martin Babler President, CEO and Chairman |
BUY
Grant, award, or other acquisition
|
Indirect |
90,804
+50.0%
|
-
|
|
Jul 01
2024
|
Martin Babler President, CEO and Chairman |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
90,804
-100.0%
|
-
|
|
Jul 01
2024
|
Mark Christopher Bradley Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
40,052
+50.0%
|
-
|
|
Jul 01
2024
|
Mark Christopher Bradley Chief Development Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
40,052
-100.0%
|
-
|
|
Jul 01
2024
|
Mark Christopher Bradley Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,978
+50.0%
|
-
|
|
Jul 01
2024
|
Mark Christopher Bradley Chief Development Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
21,978
-100.0%
|
-
|
|
Jul 01
2024
|
David M Goldstein Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
216,897
+50.0%
|
-
|
|
Jul 01
2024
|
David M Goldstein Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
216,897
-100.0%
|
-
|
|
Jul 01
2024
|
Roy C. Hardiman Chief Business & Legal Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
6,417
+50.0%
|
-
|
|
Jul 01
2024
|
Roy C. Hardiman Chief Business & Legal Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
6,417
-100.0%
|
-
|
|
Jul 01
2024
|
Roy C. Hardiman Chief Business & Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
175,401
+50.0%
|
-
|
|
Jul 01
2024
|
Roy C. Hardiman Chief Business & Legal Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
175,401
-100.0%
|
-
|